



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid  
Drug Utilization Review (DUR) Board

2:00pm

Thursday, March 10, 2016  
DMAS Board Room 13<sup>th</sup> Floor

### Agenda

1. **Call to Order and Introductions** – Randy Ferrance, MD, Chair
2. **Minutes**
  - a. Approval of Minutes from November 12, 2015 meeting
3. **New Drugs**
  - a. *Oral oncology*
    1. Alecensa® (alectinib)
    2. Cotellic™ (cobimetinib)
    3. Lonsurf® (trifluridine and tipiracil)
    4. Ninlaro® (ixazomib)
    5. Tagrisso™ (osimertinib)
  - b. *Other*
    1. Genvoya® (cobicistat;elvitegravir;emtricitabine;tenofovir alafenamide fumarate)
    2. Evzio® (naloxone auto-injector)
    3. Narcan® Nasal (naloxone nasal spray)
    4. Veltassa™ (patiromer calcium sorbitex)
  - c. *New drugs: PDL-eligible; physician-administered injectables*
4. **Service Authorizations**
  - a. Revlimid® (lenalidomide) update
  - b. Iclusig® (ponatinib) update
5. **Topics for Discussion**
  - a. Hydrocodone Utilization a year after its rescheduling as a CII
  - b. Concurrent Use of Buprenorphine with Opioids
  - c. Morphine Equivalent Dosing for Narcotics
    - Part 1: Focus on potential quantity limits
    - Part 2: Focus on member profiling/utilization review
  - d. Analysis of Compounded Medications – *follow up*



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

6. Reports
  - a. ProDUR
  - b. RetroDUR
  - c. Utilization Analysis
  - d. Top Diagnoses by Age
  - e. AAP Report
7. By-laws Biennial Review
8. Other Business
9. Adjournment



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid  
Drug Utilization Review (DUR) Board  
2:00pm  
Thursday May 12, 2016  
DMAS Board Room 13<sup>th</sup> Floor

### Agenda

1. **Call to Order and Introductions** – Randy Ferrance, MD, Chair
2. **Minutes**
  - a. Approval of Minutes from November 12, 2015 meeting
3. **New Drugs**
  - a. Odefsey® (emtricitabine, rilpivirine and tenofovir alafenamide)
  - b. *New drugs: PDL-eligible; physician-administered injectables*
4. **Service Authorizations**
  - a. Ibrance® (Palbociclib) update
5. **Topics for Discussion**
  - a. Morphine Equivalent Dosing for Narcotics and Quantity Limits
  - b. Dose Optimization
  - c. Concurrent Use of Buprenorphine with Opioids
  - d. Synagis Review
6. **Reports**
  - a. ProDUR
  - b. RetroDUR
  - c. Utilization Analysis
  - d. Top Diagnoses by Age
  - e. AAP Report
7. **Other Business**
8. **Adjournment**